In Parts 1–3, we reviewed CDK7/8 and CDK9. Here in Part 4, we turn to CDK12 and CDK13, transcriptional kinases that stabilize elongation of long DNA repair genes. They serve as “guardians” of genome stability and represent key players in synthetic lethality strategies with PARP inhibitors.
1. Basics of CDK12 & CDK13 — stabilizing Pol II elongation
Both CDK12 and CDK13 phosphorylate Pol II CTD Ser2. Their main role is to sustain transcription of long genes, especially those involved in DNA repair, genome stability, and stress responses.
1-1. Gene size dependency
DNA repair genes such as BRCA1, BRCA2, and ATR are large (>100 kb). Continuous elongation is required to fully transcribe them, making CDK12/13 indispensable.
1-2. Division of labor
- CDK12: core regulator of homologous recombination gene expression.
- CDK13: contributes to splicing regulation and RNA stability.
2. Cancer relevance — exploiting DNA repair vulnerabilities
Cancer cells accumulate DNA damage and depend on repair. Inhibition of CDK12 reduces HR gene expression, creating a homologous recombination deficiency (HRD) state. This sensitizes tumors to PARP inhibitors.
2-1. HRD tumor types
- Ovarian cancer with BRCA mutations.
- Prostate cancer (CDK12-mutated subtype).
- Triple-negative breast cancer.
2-2. Clinical implications of CDK12 mutations
In prostate cancer, CDK12 mutations define a subtype with genomic instability and potentially enhanced response to immune checkpoint blockade due to increased neoantigen load.
3. Drug discovery progress
3-1. Inhibitor candidates
- THZ531: covalent CDK12/13 inhibitor, widely used as a research tool.
- SR-4835: dual CDK12/13 inhibitor, shown to suppress DNA repair pathways preclinically.
- Other programs under development, e.g., Q-122.
3-2. Clinical development
No purely selective CDK12 inhibitor has yet reached clinical trials, but preclinical pipelines are ongoing, often in combination with PARP inhibitors.
4. Synthetic lethality — synergy with PARP inhibitors
CDK12 inhibition induces HRD, forcing reliance on PARP-mediated repair. Blocking PARP under these conditions results in lethal accumulation of DNA damage in tumor cells.
4-1. Approved PARP inhibitors
- Olaparib.
- Rucaparib.
- Niraparib.
- Talazoparib.
4-2. Expanding indications
CDK12 inhibition could extend PARP inhibitor use beyond BRCA-mutated cancers to tumors where HRD is artificially induced.
5. Challenges and resistance
- Toxicity risks, as normal cells also require DNA repair.
- Potential activation of alternative DNA repair pathways in tumors.
- Immune-related risks due to increased neoantigen load in CDK12-deficient tumors.
6. Research frontiers
- Triple combination: CDK12 inhibitors + PARP inhibitors + checkpoint blockade.
- CDK13 inhibition as a splicing vulnerability in cancer.
- Development of biomarkers for solid tumor patient selection.
7. Future perspectives
CDK12/13 inhibition represents a unique way to “create DNA repair vulnerabilities” in tumors. It may expand PARP inhibitor indications and synergize with immunotherapy to treat high-mutation-load cancers.
My Commentary
I consider CDK12/13 inhibition an extremely promising strategy to exploit tumor reliance on DNA repair. However, ensuring tumor specificity remains a key challenge. Integrating biomarkers and synthetic lethality concepts will be essential for clinical success.
Next Episode
In Part 5, we will focus on CDK11, highlighting its newly discovered pause-checkpoint role and emerging therapeutic potential.
This article was edited by the Morningglorysciences team.
Related Article
Comments